GLA
ENTA icon

Great Lakes Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Great Lakes Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-28,862
Closed -$1.14M – 524
2014
Q3 		$1.14M Buy
+28,862
New +$1.15M 0.04% 278

Other funds holding ENTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Great Lakes Advisors's ENTA Position: Q4 2014 in Review

Great Lakes Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q4 2014, closing a stake of 28,862 shares — an estimated $1.14M sold.

Great Lakes Advisors first reported a position in ENTA in Q3 2014 and held it in 1 quarter. The position peaked at $1.14M in Q3 2014. 124 funds tracked by Wall St. Rank hold ENTA as of Q4 2014.

  • Great Lakes Advisors reported no remaining Enanta Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Great Lakes Advisors sold 28,862 Enanta Pharmaceuticals shares in Q4 2014, an estimated $1.14M.
  • Great Lakes Advisors first reported a position in Enanta Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Great Lakes Advisors's Enanta Pharmaceuticals position peaked at $1.14M in Q3 2014.
  • 124 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2014.

Based on Great Lakes Advisors's 13F filing for Q4 2014, filed 11 Feb 2015.